Literature DB >> 11850252

Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.

Wataru Sugiura1, Zene Matsuda, Yoshiyuki Yokomaku, Kurt Hertogs, Brendan Larder, Tsuyoshi Oishi, Aiko Okano, Teiichirou Shiino, Masashi Tatsumi, Masakazu Matsuda, Hanae Abumi, Noboru Takata, Satoshi Shirahata, Kaneo Yamada, Hiroshi Yoshikura, Yoshiyuki Nagai.   

Abstract

We studied the evolutionary relationships between the two protease inhibitor (PI) resistance mutations, D30N and L90M, of human immunodeficiency virus type 1 (HIV-1). The former is highly specific for nelfinavir resistance, while the latter is associated with resistance to several PIs, including nelfinavir. Among patients with nelfinavir treatment failure, we found that D30N acquisition was strongly suppressed when L90M preexisted. Thus, D30N/L90M double mutations not only were detected in a very limited number of patients but also accounted for a minor fraction within each patient. In the disease course, the D30N and L90M clones readily evolved independently of each other, and later the D30N/L90M double mutants emerged. The double mutants appeared to originate from the D30N lineage but not from the L90M lineage, or were strongly associated with the former. However, their evolutionary pathways appeared to be highly complex and to still have something in common, as they always contained several additional polymorphisms, including L63P and N88D, as common signatures. These results suggest that D30N and L90M are mutually exclusive during the evolutionary process. Supporting this notion, the D30N/L90M mutation was also quite rare in a large clinical database. Recombinant viruses with the relevant mutations were generated and compared for the ability to process p55gag and p160pol precursor proteins as well as for their infectivity. L90M caused little impairment of the cleavage activities, but D30N was detrimental, although significant residual activity was observed. In contrast, D30N/L90M demonstrated severe impairment. Thus, the concept of mutual antagonism of the two mutations was substantiated biochemically and functionally.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850252      PMCID: PMC127489          DOI: 10.1128/AAC.46.3.708-715.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Two possible pathways for acquisition of mutations related to nelfinavir resistance.

Authors:  W Sugiura; T Oishi; A Okano; M Matsuda; H Abumi; K Yamada; M Koike; M Taki; M Ishikawa; T Miura; K Fukutake; K Gouchi; A Ajisawa; A Iwamoto; H Hanabusa; J Mimaya; J Takamatsu; N Takata; E Kakishita; S Higasa; S Kashiwagi; A Shirahata; Y Nagai
Journal:  Jpn J Infect Dis       Date:  1999-08       Impact factor: 1.362

Review 2.  The HIV-1 protease as a therapeutic target for AIDS.

Authors:  C Debouck
Journal:  AIDS Res Hum Retroviruses       Date:  1992-02       Impact factor: 2.205

3.  Complete mutagenesis of the HIV-1 protease.

Authors:  D D Loeb; R Swanstrom; L Everitt; M Manchester; S E Stamper; C A Hutchison
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

4.  An infectious DNA clone of HIV type 1 subtype C.

Authors:  N Mochizuki; N Otsuka; K Matsuo; T Shiino; A Kojima; T Kurata; K Sakai; N Yamamoto; S Isomura; T N Dhole; Y Takebe; M Matsuda; M Tatsumi
Journal:  AIDS Res Hum Retroviruses       Date:  1999-09-20       Impact factor: 2.205

5.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.

Authors:  M Markowitz; H Mo; D J Kempf; D W Norbeck; T N Bhat; J W Erickson; D D Ho
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

6.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

7.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

8.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor.

Authors:  J P Vacca; B D Dorsey; W A Schleif; R B Levin; S L McDaniel; P L Darke; J Zugay; J C Quintero; O M Blahy; E Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

9.  Active human immunodeficiency virus protease is required for viral infectivity.

Authors:  N E Kohl; E A Emini; W A Schleif; L J Davis; J C Heimbach; R A Dixon; E M Scolnick; I S Sigal
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

10.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity.

Authors:  C Peng; B K Ho; T W Chang; N T Chang
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

View more
  24 in total

1.  Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.

Authors:  Wataru Sugiura; Kazunori Shimada; Masakazu Matsuda; Tomoko Chiba; Lay Myint; Aiko Okano; Kaneo Yamada
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

2.  Directed HIV-1 evolution of protease inhibitor resistance by second-generation short hairpin RNAs.

Authors:  Nick C T Schopman; Anja Braun; Ben Berkhout
Journal:  Antimicrob Agents Chemother       Date:  2011-11-07       Impact factor: 5.191

3.  N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

Authors:  Yumi Mitsuya; Mark A Winters; W Jeffrey Fessel; Soo-Yon Rhee; Leo Hurley; Michael Horberg; Celia A Schiffer; Andrew R Zolopa; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2006-12       Impact factor: 2.205

Review 4.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

5.  Parameters driving the selection of nelfinavir-resistant human immunodeficiency virus type 1 variants.

Authors:  Virginie Perrin; Fabrizio Mammano
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 6.  Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.

Authors:  Robert W Shafer; Soo-Yon Rhee; Diane E Bennett
Journal:  Antivir Ther       Date:  2008

7.  Sequencing-based detection of low-frequency human immunodeficiency virus type 1 drug-resistant mutants by an RNA/DNA heteroduplex generator-tracking assay.

Authors:  Amit Kapoor; Morris Jones; R W Shafer; Soo-Yon Rhee; Powel Kazanjian; Eric L Delwart
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

8.  Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection.

Authors:  Yoshiyuki Yokomaku; Hideka Miura; Hiroko Tomiyama; Ai Kawana-Tachikawa; Masafumi Takiguchi; Asato Kojima; Yoshiyuki Nagai; Aikichi Iwamoto; Zene Matsuda; Koya Ariyoshi
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.

Authors:  Naoki Hasegawa; Wataru Sugiura; Junko Shibata; Masakazu Matsuda; Fengrong Ren; Hiroshi Tanaka
Journal:  BMC Bioinformatics       Date:  2009-10-29       Impact factor: 3.169

10.  Pairwise and higher-order correlations among drug-resistance mutations in HIV-1 subtype B protease.

Authors:  Omar Haq; Ronald M Levy; Alexandre V Morozov; Michael Andrec
Journal:  BMC Bioinformatics       Date:  2009-08-27       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.